Drug Approval | August 11, 2024
Zydus receives final approval from USFDA for Valbenazine Capsules
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Subscribe To Our Newsletter & Stay Updated
